ライフサイエンスコーパス: immunogenicity

1 enhances islet function in vitro and reduces immunogenicity.

2 eptides were tested for in vitro and ex vivo immunogenicity.

3 functional relationship between affinity and immunogenicity.

4 analyses of safety as well as evaluation of immunogenicity.

5 nt cells accumulates with aging and augments immunogenicity.

6 iter in cultured cells, while retaining high immunogenicity.

7 riants may reveal factors favoring beta-cell immunogenicity.

8 ized, immunized, and followed for safety and immunogenicity.

9 g RSV fusion protein engineered for enhanced immunogenicity.

10 ior to intervention as well as DART molecule immunogenicity.

11 were associated with an attenuation in islet immunogenicity.

12 ed for improving adenoviral vaccines-induced immunogenicity.

13 e key information for inferring neoantigens' immunogenicity.

14 anti-lymphoma activity, second infusions and immunogenicity.

15 effects that could influence liver allograft immunogenicity.

16 .38(1.01-1.89)) are strongly associated with immunogenicity.

17 adionuclide therapy (RNT) may increase tumor immunogenicity.

18 treatment, and the product can influence BP immunogenicity.

19 l for human therapy because of problems with immunogenicity.

20 exposure, no dose-limiting toxicities and no immunogenicity.

21 Peptides may induce immunogenicity.

22 onformational transitions and enhanced their immunogenicity.

23 tion rates (all p < 0.01), indicating strong immunogenicity.

24 nv influences its antigenicity and potential immunogenicity.

25 ccine target can impede its antigenicity and immunogenicity.

26 attenuated in cotton rats but retained high immunogenicity.

27 their formulation platform influences their immunogenicity.

28 ele was associated with an increased rate of immunogenicity.

29 gorithms and inferred rules of tumor epitope immunogenicity.

30 thway in cancer therapy resistance and tumor immunogenicity.

31 /paracrine IL-1beta-mediated increases in EC immunogenicity.

32 activate innate immunity to increase tumour immunogenicity.

33 WASH) may contribute to reduced oral vaccine immunogenicity.

34 efficient gene delivery and relatively mild immunogenicity.

35 o impact efficacy, stability, half-life, and immunogenicity.

36 d absolute binding affinity is predictive of immunogenicity.

37 s an optimal balance between attenuation and immunogenicity.

38 oration into the vector virion for increased immunogenicity.

39 NP trimers, which may contribute to its poor immunogenicity.

40 very to antigen-presenting cells and improve immunogenicity.

41 how egg-adaptive substitutions influence HA immunogenicity.

42 enza infection because of suboptimal vaccine immunogenicity.

43 dulating impact of H. pylori on oral vaccine immunogenicity.

44 ed with reduced graft survival and increased immunogenicity.

45 e, improving their expression and increasing immunogenicity(1).

46 HLA-DQA1*05; conversely the lowest rates of immunogenicity, 10% at 1 year, were observed in patients

47 The highest rates of immunogenicity, 92% at 1 year, were observed in patients

48 dults than in younger adults and has similar immunogenicity across all age groups after a boost dose.

49 We compared fIPV immunogenicity administered id or intramuscularly (im).

50 enicity and a lack of meaningfully increased immunogenicity after a single dose compared with the 30-

51 ld chain, while maintaining antigen-specific immunogenicity after sublingual vaccination in mice.

52 e safety in pregnant women, and benchmarking immunogenicity against a serological threshold associate

53 analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus (

54 irus types 1 and 3, and substantial/enhanced immunogenicity against poliovirus type 2 after 1 to 2 do

55 haran African country demonstrated excellent immunogenicity against poliovirus types 1 and 3, and sub

56 hat the cell-derived vaccine did not improve immunogenicity against the A(H3N2) viruses.

57 on of the CXCL12 gene, increased the rate of immunogenicity (aHR = 3.804 [2.139-6.764], p < 1 x 10-5

58 5 allele significantly increased the rate of immunogenicity (aHR = 3.9 [1.923-5.976], p < 0.0001 for

59 We investigated the immunogenicity, allergenicity, and therapeutic efficacy

60 orrect vaccine, and three were excluded from immunogenicity analyses due to incorrectly labelled samp

61 Immunogenicity analyses only included women with visits

62 Primary immunogenicity analyses were done in the per-protocol po

63 However, immunogenicity and a short serum half-life may limit the

64 peptide to AnxA5 significantly enhances its immunogenicity and antitumor efficacy when administered

65 hetical protein (HYP1), and determined their immunogenicity and association with clinical protection

66 tatus of immune synapse genes reflects tumor immunogenicity and correlates with survival.

67 Studies comparing immunogenicity and effectiveness of different influenza

68 We assess vaccine safety, immunogenicity and efficacy in several animal models.

69 eveloping improved strategies to enhance the immunogenicity and efficacy of annual influenza vaccinat

70 Here, we tested the immunogenicity and efficacy of HIV-1 C.1086 gp140 boosts

71 The safety, immunogenicity and efficacy profiles of ChAdOx1 nCoV-19

72 ine adjuvant may influence RhCMV/SIV vaccine immunogenicity and efficacy.

73 e more suited to models that better minimize immunogenicity and have a greater viral burden.IMPORTANC

74 Immunogenicity and IgA induction by the microbiota is de

75 genic and tumour-suppressor networks, tumour immunogenicity and immune cells involved in antitumour r

76 To enhance immunogenicity and mitigate the potential vaccine-induce

77 T lymphocyte response through enhanced tumor immunogenicity and optimized antigen cross-presentation.

78 actually dominate viral epitopes in putative immunogenicity and plausibly drive immune response and r

79 Thus, MerTK blockade increases tumor immunogenicity and potentiates anti-tumor immunity, whic

80 taM2-2-HindIII had excellent infectivity and immunogenicity and primed vaccine recipients for anamnes

81 In this study, we evaluated the immunogenicity and protective capacity of recombinant DE

82 We investigated the immunogenicity and protective capacity of Yersinia YopB,

83 Here, we evaluate the immunogenicity and protective efficacy (PE) of a refined

84 ted mice and guinea pigs, metformin enhances immunogenicity and protective efficacy against M. tuberc

85 Here we show the immunogenicity and protective efficacy of a single dose

86 We compared the immunogenicity and protective efficacy of two mucosal/sy

87 Children enrolled in the immunogenicity and reactogenicity sub-study will have bl

88 ntation is necessary to fully understand the immunogenicity and response magnitude to T cell epitopes

89 Immunogenicity and safety of 2 additional RZV doses were

90 This study compares the immunogenicity and safety of a 3-antigen (S/preS1/preS2)

91 We evaluated the immunogenicity and safety of an early 2-dose measles vac

92 This study assessed the immunogenicity and safety of different dosing schedules

93 We evaluated immunogenicity and safety of the adjuvanted recombinant

94 We assessed the immunogenicity and safety of three different dose schedu

95 Previously, we reported early immunogenicity and safety outcomes of a viral vector cor

96 ergizes with fatty acid-free diet to restore immunogenicity and selectively reduce mutant PIK3CA-indu

97 ation of the pharmacokinetic consequences of immunogenicity and the development of comprehensive and

98 HDAC inhibitors (HDACi) can influence tumor immunogenicity and the functional activity of specific i

99 ese models can be utilized to predict glycan immunogenicity and the pathogenicity of bacterial strain

100 Immunogenicity and therapeutic efficacy were analyzed in

101 and packaged has a profound impact on their immunogenicity and therapeutic efficacy.

102 To bypass potential anti-CAR immunogenicity and to reduce CAR binding domain size, he

103 NPNA copy number, flexibility, antigenicity, immunogenicity, and efficacy of CSP-based vaccines.

104 promote decreased tumorigenicity, increased immunogenicity, and enhanced immunotherapy response.

105 their inherent properties of tumorigenicity, immunogenicity, and heterogeneity.

106 They demonstrate good tissue diffusion, low immunogenicity, and highly selective binding to their ta

107 eld, rapid protein production, predicted low immunogenicity, and increased protein stability.

108 ptides as a facile, highly effective and low-immunogenicity approach for the protection and delivery

109 by the QAC adjuvant system (pQAC-N) enhanced immunogenicity, as evidenced by robust induction of adap

110 ational modification of histones - in tumour immunogenicity, as well as the effects of epigenetic mod

111 eactogenicity assessments or blood draws for immunogenicity assessments were masked.

112 The primary endpoints were safety and immunogenicity at day 42 after the first immunisation.

113 We evaluated immunogenicity based on hepatitis B surface (HBs) antibo

114 BP aggregates have been suggested to promote immunogenicity by acting as danger signals recognized by

115 ical/hematological parameters, cell-mediated immunogenicity by enzyme-linked immunospot, functional n

116 Optimizing these factors increases vaccine immunogenicity by up to 90-fold and maximizes the respon

117 Overexpression of cGAS/STING modifies tumor immunogenicity by upregulating PD-L1, MHC I and calretic

118 Enhanced immunogenicity can be accounted for by greater RBD uptak

119 that live bacterial virulence factor-driven immunogenicity can be uncoupled from inflammatory pathog

120 here are underlying targeting, toxicity, and immunogenicity challenges.

121 seline sera obtained during a phase 2 safety/immunogenicity clinical trial of cholera vaccine CVD 103

122 Interim safety and immunogenicity data about the vaccine candidate BNT162b1

123 We recently reported preliminary safety and immunogenicity data from a phase 1/2 trial of the ChAdOx

124 eport the available safety, tolerability and immunogenicity data from an ongoing placebo-controlled,

125 rsed for preadolescent women on the basis of immunogenicity data from randomized trials, and limited

126 Previously reported immunogenicity data from the open-label 28-d interval pr

127 The safety and immunogenicity data from this U.S. phase 1 trial of two

128 adults, added to earlier interim safety and immunogenicity data regarding BNT162b1 in younger adults

129 Overall our immunogenicity data suggests that to design a potentiall

130 g measles seroprevalence and measles vaccine immunogenicity, efficacy, and safety in HIV-infected ado

131 Immunogenicity endpoints were assessed in 562 participan

132 n related to problems regarding toxicity and immunogenicity, escalating the need for an alternative.

133 accharide-protein conjugate vaccine based on immunogenicity evaluation benchmarked against the define

134 Immunogenicity following acute EBOV infection may exist

135 n-inferiority trial (10% margin) to compared immunogenicity following administration of one versus tw

136 The moderate increase in immunogenicity following immunization and the extensive

137 increasing throughout adolescence and higher immunogenicity for younger vaccinees, vaccination before

138 ropeans, significantly increased the rate of immunogenicity (hazard ratio [HR], 1.90; 95% confidence

139 PV2-c1 and OPV2-c2) designed to have similar immunogenicity, improved genetic stability, and less pot

140 among viral vaccine antigens and hinder its immunogenicity in absolute and comparative terms.

141 struct in a mammalian system, and tested for immunogenicity in BALB/c mice.

142 ed high titers of GP38 antibodies indicating immunogenicity in humans during natural CCHFV infection.

143 based vaccine has been tested for safety and immunogenicity in humans.

144 onsiveness to repeated vaccination, and poor immunogenicity in infants of polysaccharides.

145 We compared its immunogenicity in macaques with that of a canonical ALVA

146 Selected E2 designs were tested for immunogenicity in mice, with and without hypervariable r

147 itopes to carrier proteins optimizes vaccine immunogenicity in mice.

148 tion attributes, antibody accessibility, and immunogenicity in mice.

149 e for the importance of autophagy in vaccine immunogenicity in older humans and uncovered two novel d

150 study, we explored safety, tolerability, and immunogenicity in older US adults of an investigational

151 valid target for boosting radiation therapy immunogenicity in patients with breast cancer.

152 lecular peptide nanofibers to modulate their immunogenicity in the context of immunotherapies.

153 However, immunogenicity in the double-dose group was still lower

154 culation time and significantly mitigate its immunogenicity in vivo, suggesting an EK peptide cloak a

155 ired therapeutic properties such as reducing immunogenicity, increasing stability for storage, increa

156 tumor Ag expression can mask the strength of immunogenicity induced by different cell death pathways

157 However, the level of immunogenicity induced by this vaccination schedule in I

158 ally to mice, the vaccine enhanced pulmonary immunogenicity, inducing strong Th17 responses in the lu

159 Immunogenicity is also evaluated.

160 protein expression), we showed that improved immunogenicity is likely due to increased in vivo DNA de

161 ersisted for up to 9 months, suggesting that immunogenicity is minimal under these conditions and dem

162 stimulate balanced immune responses, because immunogenicity is replication independent.

163 drawbacks, such as sensitivity to proteases, immunogenicity issues, and the development of bacterioci

164 neral, including the factors responsible for immunogenicity, its potential clinical consequences and

165 ay have altered functions and/or changed its immunogenicity, leading to an impact on disease severity

166 fers a therapeutic target; however, its poor immunogenicity limits clinical translation.

167 idely used to treat autoimmune diseases, but immunogenicity limits their efficacy for an important pr

168 y to revert to wild-type phenotype, and high immunogenicity make the designed mutants attractive vacc

169 nsideration together with its safety and low immunogenicity makes B. bacteriovorus a valid alternativ

170 This reduced immunogenicity might reflect reduced viral replication a

171 Incorporating these features into an immunogenicity model significantly improves neoantigen r

172 ng their editing efficiency, specificity and immunogenicity must be addressed.

173 This study describes the immunogenicity of 13-valent pneumococcal conjugate vacci

174 cinated at >=60 YOA and by modeling, and (2) immunogenicity of 2 additional doses administered 10Y po

175 We compared immunogenicity of 2D vs 3-dose (3D) schedules of the qua

176 500 healthy adults comparing the safety and immunogenicity of a 2-visit (days 0 and 7) intradermal (

177 We aimed to assess the efficacy, safety, and immunogenicity of a live attenuated tetravalent dengue v

178 study compared the safety, tolerability, and immunogenicity of a newly developed, tetravalent Ad26 va

179 We have reported the immunogenicity of a novel chimpanzee adenovirus-vectored

180 d.Objectives: Here, we report the safety and immunogenicity of a novel mucosal RSV F protein vaccine

181 Here, we evaluated the safety and immunogenicity of a novel, saponin (Matrix-M)-adjuvanted

182 The safety and immunogenicity of a recombinant EBOV glycoprotein (GP) n

183 We evaluated the safety and immunogenicity of a second dose of an investigational tr

184 o assess the safety and humoral and cellular immunogenicity of a single-dose and two-dose schedule in

185 We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine t

186 This study was undertaken to evaluate the immunogenicity of ACC.

187 HVTN 100 evaluated the safety and immunogenicity of an HIV subtype C pox-protein vaccine r

188 We evaluated (1) long-term immunogenicity of an initial 2-dose RZV schedule by foll

189 We aimed to assess the safety and immunogenicity of Anopheles gambiae saliva vaccine (AGS-

190 dministered as a DNA vaccine) maintained the immunogenicity of both PdSP15 and LJL143.

191 molecules, suggesting that the downregulated immunogenicity of cancer cells may contribute to the for

192 lled phase I trial (NCT03300050), safety and immunogenicity of chimeric hemagglutinin-based vaccines

193 In this study, we compared the immunogenicity of DENV2 E homodimers and DENV2 E monomer

194 To assess the immunogenicity of different parts of the spike protein,

195 ped for mRNA in vivo delivery to enhance the immunogenicity of DNA vaccines.

196 We further confirmed the immunogenicity of frameshift peptides in T cell stimulat

197 of specific antigenic sites can improve the immunogenicity of H5 vaccines.IMPORTANCE The sustained c

198 an DCs enables preclinical assessment of the immunogenicity of human vaccines in vivo.

199 gesting that chemotherapy can potentiate the immunogenicity of immune-excluded HGSOC tumors.

200 ifferences in the replication efficiency and immunogenicity of individual vaccine components.

201 We summarize the immunogenicity of leading vaccine candidates tested to d

202 ere, we provide a detailed evaluation of the immunogenicity of lipid nanoparticle-encapsulated, nucle

203 s: We evaluated the feasibility, safety, and immunogenicity of live bacillus Calmette-Guerin (BCG) in

204 The safety and immunogenicity of live respiratory syncytial virus (RSV)

205 al to evaluate the safety, tolerability, and immunogenicity of lower doses of influenza vaccine deliv

206 in the mammalian system might influence the immunogenicity of M2e with the added advantage to robust

207 This study aims to evaluate the long-term immunogenicity of measles vaccine in a sample of medical

208 icles-is a viable strategy for improving the immunogenicity of NA in an influenza virus vaccine.IMPOR

209 Here, we studied the immunogenicity of native-like recombinant envelope glyco

210 Therefore, we evaluated the immunogenicity of novel recombinant proteins correspondi

211 However, the immunogenicity of NS1 protein of Zika virus (ZIKV) is le

212 Previously, we demonstrated a potent IFN immunogenicity of nucleic acid-containing (NA-containing

213 We prospectively assessed the immunogenicity of PCV13 followed by PPSV23 in IBD patien

214 2 study evaluated safety, tolerability, and immunogenicity of PCV20 in adults without prior pneumoco

215 receptor repertoire, also contribute to the immunogenicity of peptide antigens, and some of them can

216 We therefore systematically assessed the immunogenicity of peptides containing single amino acid

217 (PT), tetanus toxoid (TT) and varicella, and immunogenicity of postchemotherapy diphtheria, tetanus,

218 es offer design principles for enhancing the immunogenicity of protein subunit vaccines.

219 The extraordinary immunogenicity of Qbeta viral-like particles relies, in

220 A small loss of immunogenicity of reduced mOPV2 was observed.

221 rimer conformation with BMS-529 improved the immunogenicity of select chimeric SOSIP trimers and elic

222 r conformational transition and improves the immunogenicity of select Env trimer immunogens.

223 chromatin, are essential in suppressing the immunogenicity of self-DNA.

224 , we evaluated the safety, tolerability, and immunogenicity of shorter, simpler regimens of trivalent

225 nd the relationship between antigenicity and immunogenicity of sIPV is not well understood.

226 Their ability to enhance and shape the immunogenicity of SOSIP trimers make these NPs a promisi

227 We report long-term safety and immunogenicity of Takeda's tetravalent dengue vaccine ca

228 cle display to optimize the antigenicity and immunogenicity of target antigens; increasing the antige

229 This study demonstrates long-term immunogenicity of the 2D HPV vaccine schedule.

230 f adjuvants is to simultaneously enhance the immunogenicity of the allergen, while precipitating the

231 tic therapies in humans raises concerns over immunogenicity of the bacterially derived Cas9 protein.

232 Secondary objectives were to assess the immunogenicity of the influenza vaccine delivered by HD-

233 sistent with officially-reported values, the immunogenicity of the measles vaccine component was unex

234 e conducted a trial in Nigeria to assess the immunogenicity of the new bOPV + IPV immunization schedu

235 To enhance the immunogenicity of the OMVs, we constructed an Asd-based

236 , phase 1-2 trial to evaluate the safety and immunogenicity of the rSARS-CoV-2 vaccine (in 5-mug and

237 We aimed to assess safety and immunogenicity of the two novel OPV candidates compared

238 safety and exploratory humoral and cellular immunogenicity of the vaccine, from subgroups of volunte

239 oung adults, and now describe the safety and immunogenicity of this vaccine in a wider range of parti

240 in multivalent vaccination regimens and the immunogenicity of trimers derived from elite neutralizer

241 ncovers the widespread occurrence and strong immunogenicity of tumor-specific antigens derived from s

242 However, endosomal trapping and low immunogenicity of tumour antigens usually limit the effi

243 the immune system to eliminate and shape the immunogenicity of tumours defines the process of cancer

244 placebo-controlled study assessed safety and immunogenicity of two-dose regimens of Ad26.ZEBOV (Ad26)

245 Early data confirm safety, tolerability, and immunogenicity of typhoid conjugate vaccine, and early e

246 Immunogenicity of vaccines is often worse in older adult

247 , given that bone-marrow might promote graft immunogenicity or graft-versus-host disease.

248 This limits their application owing to immunogenicity or transgene silencing.

249 en doses and 2-year follow-up for safety and immunogenicity outcomes.

250 ssed because of concerns regarding potential immunogenicity, parenteral delivery, and cost.

251 identify and study glycan motifs involved in immunogenicity, pathogenicity, molecular mimicry, and im

252 tructure profoundly impacts on their in vivo immunogenicity, pharmacokinetics, and functional attribu

253 could have the benefit of reducing potential immunogenicity problems.

254 The immunogenicity profile (8% anti-drug antibodies) was con

255 ity DeltaGu = 24.3 kJ/mol) and a sub-optimal immunogenicity profile.

256 ural changes in the mAb can lead to unwanted immunogenicity, reduced efficacy, and loss of material d

257 , and the parameters governing tumor epitope immunogenicity remain unclear.

258 itical to enhance the stability and minimize immunogenicity risk of biotherapeutics.

259 This study reports immunogenicity, safety, and interchangeability of a sing

260 verse events and serious adverse events, and immunogenicity (seroprotection rates on day 28 after the

261 Mouse immunogenicity studies revealed that similar polyclonal

262 The outcome of previous immunogenicity studies suggests that the limited accessi

263 IV-PT123) for ALVAC in a phase 1b safety and immunogenicity study.

264 5 years, 56-69 years, and 70 years and older immunogenicity subgroups.

265 assessed in 562 participants enrolled in the immunogenicity subset, of whom 509 were included in the

266 ype to month 48 assessed in the per-protocol immunogenicity subset.

267 d, extreme thermotolerance, and satisfactory immunogenicity suggest that such RBD subunit vaccine for

268 In some specialties, immunogenicity testing is becoming a part of routine cli

269 ated influenza vaccine gave slightly greater immunogenicity than did a single-dose regimen in pregnan

270 ition, we developed a model of tumor epitope immunogenicity that filtered out 98% of non-immunogenic

271 iosimilars has sparked a renewed interest in immunogenicity that has resulted in the development of i

272 e-specific responses to injury and increased immunogenicity, thereby aggravating transplant outcomes.

273 mmune signalling by genetic vectors modifies immunogenicity, they also emphasise the difficulty in ge

274 binding capacity fivefold and increased its immunogenicity threefold in terms of IgG generation.

275 load in tumor cell vaccines increases their immunogenicity to drive anti-tumor therapy in combinatio

276 ht into the vaccine design and evaluation of immunogenicity to enable rapid translation to the clinic

277 use neurovirulence test, and were similar in immunogenicity to recombinant poxvirus NYVAC-HIV vectors

278 protein regimens is warranted given enhanced immunogenicity to the V1V2 correlates of decreased HIV-1

279 istically with specific allergens to enhance immunogenicity to worsen asthma in susceptible subjects.

280 binant influenza vaccine [RIV4]), safety and immunogenicity trial of qNIV (in 5 different doses/formu

281 ed with poor CT responses exhibited improved immunogenicity upon invasion of bacterial taxa from cage

282 21, blood specimens were collected to assess immunogenicity using hemagglutination inhibition, micron

283 cimens were also collected to assess mucosal immunogenicity using kinetic IgA ELISA.

284 and systemic reactions and adverse events); immunogenicity was a secondary outcome.

285 st (flagellin; FliC) on vaccine efficacy and immunogenicity was also examined.

286 lacebo were included in the safety analysis; immunogenicity was analysed using the per-protocol popul

287 Immunogenicity was assessed by measuring serotype-specif

288 Immunogenicity was defined as an anti-drug antibody tite

289 Vaccine immunogenicity was demonstrated in mice with potent and

290 Vaccine immunogenicity was measured by hemagglutination-inhibiti

291 Immunogenicity was recognized as a potential limitation

292 The primary endpoint for immunogenicity was the percentage of subjects with an ad

293 To increase mvPC's immunogenicity, we added a synthetic adjuvant (RS09) to

294 ne if C. burnetii cultured in ACCM-2 retains immunogenicity, we compared the protective efficacies of

295 Safety and immunogenicity were assessed through 1-year postdosing.

296 was relatively limited and assays to measure immunogenicity were less sophisticated than today.

297 Safety and immunogenicity were the respective primary and secondary

298 w that both mouse and human iPSCs lose their immunogenicity when major histocompatibility complex (MH

299 tion of ovalbumin to laminarin increased its immunogenicity while at the same time reducing local sid

300 the "glycan shield," is a key determinant of immunogenicity, yet intrinsic heterogeneity confounds ty